---
title: "Weekly Recap | Capricor Therap -11.62%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302949752.md"
description: "Capricor Therap fell 11.62% this week to close at $5.93, while the S&P 500 slipped 0.47%. The stock underperformed the benchmark by roughly 11.15 percentage points. The week opened at $6.82 on Monday and touched an intraday high of $6.93 before settling at $6.65. Wednesday brought a sharp move lower, with the stock breaking below $6 and hitting a week low of $5.79. It rebounded to $6.13 on Thursday, then pulled back to $5.93 on Friday."
datetime: "2026-10-24T06:03:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302949752.md)
  - [en](https://longbridge.com/en/news/302949752.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302949752.md)
generator: "portal-rs"
---

# Weekly Recap | Capricor Therap -11.62%, consensus target above spot

## The Week

Capricor Therap fell 11.62% this week to close at $5.93, while the S&P 500 slipped 0.47%. The stock underperformed the benchmark by roughly 11.15 percentage points. The week opened at $6.82 on Monday and touched an intraday high of $6.93 before settling at $6.65. Wednesday brought a sharp move lower, with the stock breaking below $6 and hitting a week low of $5.79. It rebounded to $6.13 on Thursday, then pulled back to $5.93 on Friday. There was no major catalyst, and volume ran about 27% below its recent daily median.

## Analyst Ratings

Among the 10 brokers covering the stock, 3 rate it buy, 1 rate it overweight, and 6 rate it hold; none carry a sell or underweight rating. The consensus rating is buy, with a consensus target of $27 — about 355% above the current price. Individual targets range widely from $7 to $54. Within the biotechnology industry, the stock ranks 158th out of 511 names, placing it in the lower middle of the group.

## The Week Ahead

The macro calendar is busy next week. Tuesday brings durable goods orders, FHFA house prices, the Case Shiller 20-city index, new home sales, and consumer confidence. There are no company-specific events on the near-term calendar. Capricor’s next earnings release is scheduled for 11 November after market close, covering fiscal Q3 2026; consensus estimates point to a loss of $0.42 per share on revenue of $10.4m.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)

## Related News & Research

- [Capricor Therapeutics (CAPR) Could Be 89% Undervalued Following Deramiocel And Loss Concerns](https://longbridge.com/en/news/296098763.md)
- [Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why](https://longbridge.com/en/news/295887955.md)
- [VSBLTY Partners With QuadGen to License AI Platform for India’s Smart Cities](https://longbridge.com/en/news/304742065.md)
- [Raised Guidance Could Cement Clover Health Stock’s First Profitable Year](https://longbridge.com/en/news/304738480.md)
- [Biogen (BIIB) Alzheimer’s Updates Put Fair Value Questions Back In Focus](https://longbridge.com/en/news/304738186.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**